Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

squiggleburp Oct. 7 at 1:40 AM

$RGNX Strong close. Very nice move!!!! Still long, sitting patiently-

0 · Reply

rando321456 Oct. 6 at 9:07 PM

$RGNX Lets say SR RGX-314 gets 1% of the prevalent Wet AMD population annually, there'll be about 2.5 million patients across their geographies by the time they launch in 2028. That's about 25k treatments a year at probably an average price of 30k. Gross that's 750 million in revenue, lets say about 30% makes its way back to Regenx after profit sharing and other costs. That's 225 million in flow throughs. Add ontop of that ~150 million in flow through for RGX-121 and ~200 million for Zolegensma after the label extension is approved. Then imagine RGX-202 ontop of all of that. Idk we're very rapidly approaching an overwhelming position here, still could go belly up as this is bioworld, but 2026 could be quite the year. Good luck all.

1 · Reply

WaveRB77 Oct. 6 at 2:27 PM

$RGNX Rgnx done enrolling people in the Ascent and Atmosphere trials for RG 314.The train keeps moving.

0 · Reply

DCRMIA Oct. 5 at 3:10 PM

$RGNX Upcoming presentation of 12-month functional data for RGX-202 at the World Muscle Society congress on October 8, with Phase I/II safety results reinforcing upside 🚀🚀📈📈🇺🇸🇺🇸

0 · Reply

Doozio Oct. 4 at 10:10 PM

$RGNX yo Roger. It’s 🐒🍌🧠⏰♾️

0 · Reply

Leeroimiguel Oct. 3 at 3:18 PM

$RGNX can only see this going one way long term , adding more 👍🏻

0 · Reply

BRITLS Oct. 2 at 8:07 PM

$RGNX We going down tomorrow or was this move on substance? thing is so volatile but trending up!

1 · Reply

Cashmoneyt Oct. 2 at 6:40 PM

$RGNX Just the beginning

0 · Reply

WaveRB77 Oct. 2 at 6:13 PM

$RGNX buy in now folks.its been a long 6 years of waiting!!!

1 · Reply

rando321456 Oct. 1 at 2:03 PM

$RGNX List of assets in clinical trials owned or that Regenx gets slice of: RGX-121 RGX-111 RGX-202 RGX-314 SR RGX-314 SCS RGX-181(licensed to Tern) RGX-381(licensed to Tern) UX701(Ultragenyx) DTX301(Ultragenyx) DTX401(Ultragenyx) RP-A501(Rocket) AMT-260(Uniqure) LY3884961(Lilly) LY3884963(Lilly) Zolgensma(Novartis)

2 · Reply

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Sep 29, 2025, 7:05 AM EDT - 7 days ago

REGENXBIO Announces Presentation at the World Muscle Society

Sep 9, 2025, 6:12 AM EDT - 27 days ago

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 8, 2025, 2:05 PM EDT - 4 weeks ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 6, 2025, 8:29 AM EDT - 4 weeks ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 5, 2025, 7:05 AM EDT - 4 weeks ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Aug 28, 2025, 7:05 AM EDT - 5 weeks ago

REGENXBIO to Participate in Upcoming Investor Conferences

Aug 19, 2025, 12:01 PM EDT - 6 weeks ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 18, 2025, 5:00 PM EDT - 7 weeks ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 8, 2025, 9:11 AM EDT - 2 months ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 2 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 3 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 6, 2025, 4:02 PM EDT - 4 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 5, 2025, 11:43 AM EDT - 4 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 19, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 14, 2025, 7:13 AM EDT - 5 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 13, 2025, 7:07 AM EDT - 5 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 8, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Mar 26, 2025, 12:31 PM EDT - 6 months ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 7 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 7 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 7 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 7 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 7 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 11, 2025, 3:20 PM EST - 8 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 8 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 9 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 9 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 9 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 9 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 10 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 11 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 11 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 11 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 11 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 1 year ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 3, 2024, 8:04 AM EDT - 1 year ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

squiggleburp Oct. 7 at 1:40 AM

$RGNX Strong close. Very nice move!!!! Still long, sitting patiently-

0 · Reply

rando321456 Oct. 6 at 9:07 PM

1 · Reply

WaveRB77 Oct. 6 at 2:27 PM

$RGNX Rgnx done enrolling people in the Ascent and Atmosphere trials for RG 314.The train keeps moving.

0 · Reply

DCRMIA Oct. 5 at 3:10 PM

0 · Reply

Doozio Oct. 4 at 10:10 PM

$RGNX yo Roger. It’s 🐒🍌🧠⏰♾️

0 · Reply

Leeroimiguel Oct. 3 at 3:18 PM

$RGNX can only see this going one way long term , adding more 👍🏻

0 · Reply

BRITLS Oct. 2 at 8:07 PM

$RGNX We going down tomorrow or was this move on substance? thing is so volatile but trending up!

1 · Reply

Cashmoneyt Oct. 2 at 6:40 PM

$RGNX Just the beginning

0 · Reply

WaveRB77 Oct. 2 at 6:13 PM

$RGNX buy in now folks.its been a long 6 years of waiting!!!

1 · Reply

rando321456 Oct. 1 at 2:03 PM

2 · Reply

squiggleburp Sep. 30 at 9:44 PM

$RGNX Someone hit a 270k share eject button on the close today. Yuck

0 · Reply

squiggleburp Sep. 30 at 12:15 PM

$FBIO TNXP PDUFA came after hours. Initially I was thinking that was a beautiful play because there are no LUDP halts after hours. That one didn’t work out because they diluted into the run. This decision could happen at any point today. It will halt pending news. Mid day may be the answer here? Still holding all of my shares. Very exciting times. $RGNX February. They already sat through and corrected a CRL. That’s my next BIO play. No, No, GALT and SLS too! SLS large position. GALT angleing in!

3 · Reply

squiggleburp Sep. 29 at 6:30 PM

$RGNX Three taps at the $10.00 mark over the past several weeks. Another rejection and we may trade down so I can top off my position!

0 · Reply

squiggleburp Sep. 29 at 5:18 PM

$RGNX Still long and strong! 💪

0 · Reply

maphere Sep. 29 at 3:42 PM

$CLSD $RGNX In 3 weeks (Oct.18-20) at AAO: Section IX: Late Breaking Developments, Part I Suprachoroidal Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): First Time 2-Year Results in Non-Proliferative Diabetic Retinopathy Charles C Wykoff, MD, PhD https://aao.apprisor.org/apsSession.cfm?id=RET11

2 · Reply

waugusti Sep. 29 at 2:02 PM

$RGNX the long march to the summit begins now.

1 · Reply

squiggleburp Sep. 26 at 5:34 PM

$RGNX Whoa whoa whoa!!! Welcome to the party yall!!!!!!

0 · Reply

Say_Wen Sep. 26 at 5:30 PM

$RGNX Feb is our closest big catalyst, right? PT around $35?

0 · Reply

rando321456 Sep. 26 at 2:51 AM

$RGNX With Uniqure's recent move I do want to highlight that we have a deal with them around a MTLE asset that reduced seizures by 92% in the first patient.(need more data but still) As far as I can tell Regenx has patent coverage in the area through 2042/2043 and winds up with ~8% flow throughs.

2 · Reply

squiggleburp Sep. 24 at 11:02 PM

$RGNX Nice recovery today. My mountain of shares grew during the dip!

0 · Reply

squiggleburp Sep. 23 at 8:16 PM

$RGNX Pulled my average down a pinch. We are super early here. Perhaps we get an analyst price target increase or a PR. PT for this stock is way way higher!

0 · Reply

Bbboston Sep. 23 at 12:22 PM

$RGNX Found this a bit too late. Should have entered between 5-6. Where is this going?

1 · Reply

Market Cap	526.86M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-272.53%
Debt to Equity Ratio	0.00

Volume	698,900
Avg Vol	600,890
Day's Range	N/A - N/A
Shares Out	50.51M
Stochastic %K	74%
Beta	1.17
Analysts	Strong Sell
Price Target	$30.08